FDA Warnings About GMP Violations Aren’t The First For Three US OTC Drug Manufacturers
Executive Summary
Ultra Seal, Generitech, and Yusef Manufacturing indicated in responses to FDA inspectors’ findings they weren’t aware of, or capable for complying with some of the requirements imposed on them under FDA regulations for ingredient and product testing and other components of quality control.
You may also be interested in...
‘Temperature Abuse’ Heated US Drug Recalls To Record Level In FY2022, FDA Finds
Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.
‘Temperature Abuse’ Led Drug Recalls To New Heights In FY 2022, US FDA Finds
Surveillance inspections nearly tripled as drug recalls reached highest level in five years, finds agency’s FY 2022 “state of pharmaceutical quality” report. Meanwhile, analysis points to lack of domestic API sources for many essential medicines.
Get ‘Responsive,’ Not ‘Defensive’ When US FDA Finds GMP Problems, Consultant Advises
Responses to form 483s, including effectiveness of CAPA plan for each problem, determines whether enforcement door opens or closes, says Teresa Gorecki of Compliance Architects. “I see companies sitting at that point … the organization either moves into a defensive mode or responsive mode.”